Evaluation of Benzguinols as Next-Generation Antibiotics for the Treatment of Multidrug-Resistant Bacterial Infections

Simple item page
dc.contributor.authorNguyen, H.T.
dc.contributor.authorMorshed, M.T.
dc.contributor.authorVuong, D.
dc.contributor.authorCrombie, A.
dc.contributor.authorLacey, E.
dc.contributor.authorGarg, S.
dc.contributor.authorPi, H.
dc.contributor.authorWoolford, L.
dc.contributor.authorVenter, H.
dc.contributor.authorPage, S.W.
dc.contributor.authorPiggott, A.M.
dc.contributor.authorTrott, D.J.
dc.contributor.authorOgunniyi, A.D.
dc.date.issued2021
dc.description.abstractOur recent focus on the “lost antibiotic” unguinol and related nidulin-family fungal natural products identified two semisynthetic derivatives, benzguinols A and B, with unexpected in vitro activity against Staphylococcus aureus isolates either susceptible or resistant to methicillin. Here, we show further activity of the benzguinols against methicillin-resistant isolates of the animal pathogen Staphylococcus pseudintermedius, with minimum inhibitory concentration (MIC) ranging 0.5–1 mg/mL. When combined with sub-inhibitory concentrations of colistin, the benzguinols demonstrated synergy against Gram-negative reference strains of Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa (MICs of 1–2 mg/mL in the presence of colistin), whereas the benzguinols alone had no activity. Administration of three intraperitoneal (IP) doses of 20 mg/kg benzguinol A or B to mice did not result in any obvious adverse clinical or pathological evidence of acute toxicity. Importantly, mice that received three 20 mg/kg IP doses of benzguinol A or B at 4 h intervals exhibited significantly reduced bacterial loads and longer survival times than vehicle-only treated mice in a bioluminescent S. aureus murine sepsis challenge model. We conclude that the benzguinols are potential candidates for further development for specific treatment of serious bacterial infections as both stand-alone antibiotics and in combination with existing antibiotic classes.
dc.description.statementofresponsibilityHang Thi Nguyen, Mahmud T. Morshed, Daniel Vuong, Andrew Crombie, Ernest Lacey, Sanjay Garg, Hongfei Pi, Lucy Woolford, Henrietta Venter, Stephen W. Page, Andrew M. Piggott, Darren J. Trott, and Abiodun D. Ogunniyi
dc.identifier.citationAntibiotics, 2021; 10(6):727-1-727-17
dc.identifier.doi10.3390/antibiotics10060727
dc.identifier.issn2079-6382
dc.identifier.issn2079-6382
dc.identifier.orcidWoolford, L. [0000-0001-7271-2937]
dc.identifier.orcidTrott, D.J. [0000-0002-8297-5770]
dc.identifier.orcidOgunniyi, A.D. [0000-0001-9308-5629]
dc.identifier.urihttps://hdl.handle.net/2440/145856
dc.language.isoen
dc.publisherMDPI AG
dc.rights© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
dc.source.urihttps://doi.org/10.3390/antibiotics10060727
dc.subjectStaphylococcus pseudintermedius; Staphylococcus aureus; benzguinols; nidulins; Gramnegative; antimicrobial resistance; colistin; bioluminescent mouse model; cytotoxicity; minimum inhibitory concentration
dc.titleEvaluation of Benzguinols as Next-Generation Antibiotics for the Treatment of Multidrug-Resistant Bacterial Infections
dc.typeJournal article
pubs.publication-statusPublished

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
hdl_145856.pdf
Size:
4.94 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Research Outputs